News
CLRB
3.110
-2.51%
-0.080
Weekly Report: what happened at CLRB last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at CLRB last week (0408-0412)?
Weekly Report · 04/15 12:23
Weekly Report: what happened at CLRB last week (0401-0405)?
Weekly Report · 04/08 12:29
Weekly Report: what happened at CLRB last week (0325-0329)?
Weekly Report · 04/01 12:24
Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials
TipRanks · 03/28 19:25
Cellectar Biosciences Price Target Raised to $28.00/Share From $20.00 by Roth MKM
Dow Jones · 03/28 17:13
Cellectar Biosciences Is Maintained at Buy by Roth MKM
Dow Jones · 03/28 17:13
Roth MKM Maintains Buy on Cellectar Biosciences, Raises Price Target to $28
Benzinga · 03/28 17:03
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
TipRanks · 03/28 11:50
Cellectar Biosciences Price Target Raised to $12.00/Share From $11.00 by Oppenheimer
Dow Jones · 03/28 11:43
Oppenheimer Reiterates Outperform on Cellectar Biosciences, Raises Price Target to $12
Benzinga · 03/28 11:33
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
RDDT stock is down 13.4% as of Wednesday morning. The Hedgeye analyst is warning clients that Reddit stock is going to see a major dip after recently going public. The social media company's shares are already down more than 10% this morning. Gamida Cell (NASDAQ:GMDA) stock is falling, Joann stock is preparing for suspension and earnings from Cellectar Biosciences.
Investorplace · 03/27 15:35
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell stock is down 82.3% as of Wednesday morning. The company is entering into a restructuring agreement with funds to go private. More than 81 million shares of GMDA stock are changing hands. Joann, Cellectar Biosciences and Lands' End stock are also moving on Wednesday.
Investorplace · 03/27 15:16
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
Cellectar Biosciences reported earnings per share of -40 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -59 cents. Cellectar didn't report any revenues for the first quarter.
Investorplace · 03/27 14:53
Cellectar Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Cellectar Biosciences Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 61 cents per share. The mean expectation of four analysts was for a loss of 57 cents. The average analyst rating on the shares is "strong buy"
Reuters · 03/27 13:31
Options Volatility and Implied Earnings Moves Today, March 27, 2024
TipRanks · 03/27 12:05
Cellectar Biosciences Q4 EPS $(0.40) Beats $(0.59) Estimate
Benzinga · 03/27 10:51
Cellectar Biosciences GAAP EPS of -$3.11 misses by $0.28
Seeking Alpha · 03/27 10:47
*Cellectar Biosciences 2023 Research and Development Expense About $28.2M >CLRB
Dow Jones · 03/27 10:43
*Cellectar Biosciences 2023 Loss/Shr $3.11 >CLRB
Dow Jones · 03/27 10:42
More
Webull provides a variety of real-time CLRB stock news. You can receive the latest news about Cellectar Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).